BRAF and colorectal carcinoma: Such improved therapeutic applications are currently not available for KRAS- and BRAF-mutated CRC, however we have previously described a reversible negative impact of the KRAS oncogene and activated MAPK signaling onto MHC-I expression in CRC cells [147].